Protein Signature of Lung Cancer Tissues
暂无分享,去创建一个
Sheri K. Wilcox | L. Gold | W. Xiong | Jeffrey J. Walker | T. Jarvis | N. Janjić | E. Brody | G. Baird | M. Mehan | D. Thirstrup | Deborah Ayers | R. Ostroff
[1] V. Cogliano. International Agency for Research on Cancer (IARC) , 2018, The Grants Register 2019.
[2] M. L. R. D. Christenson,et al. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .
[3] S. Digumarthy,et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] Kwon-Sik Park,et al. Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. , 2011, Cancer cell.
[5] C. Gatsonis,et al. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .
[6] Iver Petersen,et al. IGFBP7 is a p53 target gene inactivated in human lung cancer by DNA hypermethylation. , 2011, Lung cancer.
[7] J. Ioannidis,et al. Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses. , 2011, JAMA.
[8] P. Bossuyt. The thin line between hope and hype in biomarker research. , 2011, JAMA.
[9] Sheri K. Wilcox,et al. Rapid Histochemistry Using Slow Off-rate Modified Aptamers With Anionic Competition , 2011, Applied immunohistochemistry & molecular morphology : AIMM.
[10] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[11] Ugo Pastorino,et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer , 2011, Proceedings of the National Academy of Sciences.
[12] E. Diamandis,et al. Cancer biomarkers: can we turn recent failures into success? , 2010, Journal of the National Cancer Institute.
[13] K. Hirata,et al. Role of endothelial cell-selective adhesion molecule in hematogeneous metastasis. , 2010, Microvascular research.
[14] Tracy R. Keeney,et al. Aptamer-based multiplexed proteomic technology for biomarker discovery , 2010, Nature Precedings.
[15] Stephen A. Williams,et al. Unlocking Biomarker Discovery: Large Scale Application of Aptamer Proteomic Technology for Early Detection of Lung Cancer , 2010, PloS one.
[16] L. Puricelli,et al. Mast cell phenotypes and microvessels in non-small cell lung cancer and its prognostic significance. , 2010, Human pathology.
[17] C. Reed,et al. Differential matrix metalloproteinase levels in adenocarcinoma and squamous cell carcinoma of the lung. , 2010, The Journal of thoracic and cardiovascular surgery.
[18] Y. Ishikawa,et al. Role of insulin-like growth factor binding protein 2 in lung adenocarcinoma: IGF-independent antiapoptotic effect via caspase-3. , 2010, The American journal of pathology.
[19] L. Tanoue,et al. Molecular Origins of Cancer. Lung Cancer , 2010 .
[20] J. Wang,et al. Receptor for advanced glycation end products (RAGE) soluble form (sRAGE): a new biomarker for lung cancer. , 2010, Neoplasma.
[21] Soo Young Lee,et al. MicroRNA Expression Profiles in Korean Non-Small Cell Lung Cancer , 2009 .
[22] J. Roth,et al. Application of the revised lung cancer staging system (IASLC Staging Project) to a cancer center population. , 2009, The Journal of thoracic and cardiovascular surgery.
[23] Masato Nakamura,et al. Cancerous, but not stromal, thrombospondin-2 contributes prognosis in pulmonary adenocarcinoma. , 2009, Oncology reports.
[24] O. Topolcan,et al. Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease. , 2009, Anticancer research.
[25] D. Beer,et al. Upregulated INHBA expression may promote cell proliferation and is associated with poor survival in lung adenocarcinoma. , 2009, Neoplasia.
[26] L. Qian,et al. Microvessel Density and Expression of Thrombospondin-1 in Non-small Cell Lung Cancer and Their Correlation with Clinicopathological Features , 2009, The Journal of international medical research.
[27] Polina Golland,et al. Scoring diverse cellular morphologies in image-based screens with iterative feedback and machine learning , 2009, Proceedings of the National Academy of Sciences.
[28] C. Lee,et al. Caspase‐3 enhances lung metastasis and cell migration in a protease‐independent mechanism through the ERK pathway , 2008, International journal of cancer.
[29] M. Schmitt,et al. Expression of metalloprotease insulin-degrading enzyme (insulysin) in breast and ovarian cancer tissues , 2008 .
[30] W. Sessa,et al. Thrombospondin-2 modulates extracellular matrix remodeling during physiological angiogenesis. , 2008, The American journal of pathology.
[31] B. Jeon,et al. Alteration of APE1/ref-1 expression in non-small cell lung cancer: the implications of impaired extracellular superoxide dismutase and catalase antioxidant systems. , 2008, Lung cancer.
[32] A. Jemal,et al. Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.
[33] J. Soria,et al. Gene expression profiling of non-small-cell lung cancer , 2008, Expert review of molecular diagnostics.
[34] M. Schmitt,et al. Expression of metalloprotease insulin-degrading enzyme insulysin in normal and malignant human tissues. , 2008, International journal of molecular medicine.
[35] Cheng-Long Huang,et al. Overexpression of matrix metalloproteinase-7 (MMP-7) correlates with tumor proliferation, and a poor prognosis in non-small cell lung cancer. , 2007, Lung cancer.
[36] Lin Feng,et al. Identification of genes differentially expressed in human primary lung squamous cell carcinoma. , 2007, Lung cancer.
[37] M. Pacyna‐Gengelbach,et al. Insulin‐like growth factor binding protein‐related protein 1 (IGFBP‐rP1) has potential tumour‐suppressive activity in human lung cancer , 2007, The Journal of pathology.
[38] Anne E Carpenter,et al. CellProfiler: image analysis software for identifying and quantifying cell phenotypes , 2006, Genome Biology.
[39] G. Watanabe,et al. Surgical results in T2N0M0 nonsmall cell lung cancer patients with large tumors 5 cm or greater in diameter: what regulates outcome? , 2006, The Annals of thoracic surgery.
[40] S. Burdach,et al. Identification and classification of differentially expressed genes in non-small cell lung cancer by expression profiling on a global human 59.620-element oligonucleotide array. , 2006, Oncology reports.
[41] N. Sun,et al. Expression of nuclear factor-kappaB and its clinical significance in nonsmall-cell lung cancer. , 2006, The Annals of thoracic surgery.
[42] G. Cavet,et al. Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients , 2005, Clinical Cancer Research.
[43] N. Carter,et al. Genome-Wide Screening of Genomic Alterations and Their Clinicopathologic Implications in Non–Small Cell Lung Cancers , 2005, Clinical Cancer Research.
[44] Raphael A Nemenoff,et al. Tumorigenesis and Neoplastic Progression Analysis of Orthologous Gene Expression between Human Pulmonary Adenocarcinoma and a Carcinogen-Induced Murine Model , 2010 .
[45] Günther Richter,et al. Matrix metalloproteinase-12 expression correlates with local recurrence and metastatic disease in non-small cell lung cancer patients. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[46] Rolf-Edgar Silber,et al. Down-regulation of the Receptor for Advanced Glycation End-products (rage) Supports Non-small Cell Lung Carcinoma , 2004 .
[47] M. Okada,et al. Effect of tumor size on prognosis in patients with non-small cell lung cancer: the role of segmentectomy as a type of lesser resection. , 2005, The Journal of thoracic and cardiovascular surgery.
[48] M. Tada,et al. Prediction of lymph node metastasis by analysis of gene expression profiles in non-small cell lung cancer. , 2004, The Journal of surgical research.
[49] Hoon-Kyo Kim,et al. Expression of caspase-3 and c-myc in non-small cell lung cancer. , 2004, Cancer research and treatment : official journal of Korean Cancer Association.
[50] K. Hiroshima,et al. Overexpression of Collagen XVIII Is Associated with Poor Outcome and Elevated Levels of Circulating Serum Endostatin in Non–Small Cell Lung Cancer , 2004, Clinical Cancer Research.
[51] Jianzhong Su,et al. Quantitative detection of interleukin 8 gene expression in lung cancer by real—time polymerase chain reaction , 2004 .
[52] T. Hiwasa,et al. Increased expression of collagen XVIII and its prognostic value in nonsmall cell lung carcinoma , 2004, Cancer.
[53] S. Wiseman,et al. Altered E-cadherin and epidermal growth factor receptor expressions are associated with patient survival in lung cancer: a study utilizing high-density tissue microarray and immunohistochemistry , 2004, Modern Pathology.
[54] P. Allavena,et al. From pattern recognition receptor to regulator of homeostasis: the double-faced macrophage mannose receptor. , 2004, Critical reviews in immunology.
[55] H. Kato,et al. cDNA microarray analysis of gene expression in pathologic stage IA nonsmall cell lung carcinomas , 2003, Cancer.
[56] B. Stewart,et al. World Cancer Report , 2003 .
[57] David E. Misek,et al. RANTES expression is a predictor of survival in stage I lung adenocarcinoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[58] John D. Storey. A direct approach to false discovery rates , 2002 .
[59] E. Gabrielson,et al. High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] Yih-Leong Chang,et al. The significance of E-cadherin and α-, β-, and γ-catenin expression in surgically treated non–small cell lung cancers of 3 cm or less in size , 2002 .
[61] I. Shimon,et al. Elevated Insulin-Like Growth Factor-1 and Insulin-Like Growth Factor Binding Protein-2 in Malignant Pleural Effusion , 2002, Acta oncologica.
[62] Yih-Leong Chang,et al. The significance of E-cadherin and alpha-, beta-, and gamma-catenin expression in surgically treated non-small cell lung cancers of 3 cm or less in size. , 2002, The Journal of thoracic and cardiovascular surgery.
[63] S. Erzurum,et al. Differential expression of manganese superoxide dismutase and catalase in lung cancer. , 2001, Cancer research.
[64] B. Rybarczyk,et al. Tumors and Fibrinogen , 2001, Annals of the New York Academy of Sciences.
[65] P. Bornstein,et al. Thrombospondin 2, a matricellular protein with diverse functions. , 2000, Matrix biology : journal of the International Society for Matrix Biology.
[66] A. Yuan,et al. Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer. , 2000, American journal of respiratory and critical care medicine.
[67] J. Foekens,et al. The urokinase-type plasminogen activator system in resected non-small-cell lung cancer. Rotterdam Oncology Thoracic Study Group. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[68] J. Foekens,et al. The urokinase-type plasminogen activator system in resected non-small-cell lung cancer. Rotterdam Oncology Thoracic Study Group. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[69] E. Brambilla,et al. Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[70] C. Angeletti,et al. Expression of vascular endothelial growth factor mRNA in non-small-cell lung carcinomas , 1999, British Journal of Cancer.
[71] C. Angeletti,et al. Thrombospondins I and II messenger RNA expression in lung carcinoma: relationship with p53 alterations, angiogenic growth factors, and vascular density. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[72] Y. Oshika,et al. Thrombospondin 2 gene expression is correlated with decreased vascularity in non-small cell lung cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[73] K. Yasumoto,et al. Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma. , 1998, The Journal of thoracic and cardiovascular surgery.
[74] P. Schraml,et al. Differential messenger RNA and protein expression of the receptor for advanced glycosylated end products in normal lung and non-small cell lung carcinoma. , 1997, Cancer research.
[75] G. Fontanini,et al. 607 Vascular endothelial growth factor (VEGF) in non small cell lung carcinomas (NSCLC): Prognostic implications , 1997 .
[76] G. Jaques,et al. Molecular cloning of IGFBP-5 from SCLC cell lines and expression of IGFBP-4, IGFBP-5 and IGFBP-6 in lung cancer cell lines and primary tumours. , 1993, European journal of cancer.
[77] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[78] H. Dvorak,et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.